Catherine A. Shu

NewYork–Presbyterian Hospital — United States

Medicine · Health Sciences

30h-index4.0kcitations292works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(115), Colorectal Cancer Treatments and Studies(88), Cancer Genomics and Diagnostics(67), Genetic factors in colorectal cancer(36), Lung Cancer Research Studies(35)

Publications291 total

Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Anjali Saqi(14), Naiyer A. Rizvi(12), Roland E. Knoblauch(11), Meena Thayu(10), Byoung Chul Cho(10), Joshua K. Sabari(9), Alexander I. Spira(7), Rachel E. Sanborn(7), Joshua Bauml(7), John V. Heymach(7), Mark M. Awad(6), Mark Stoopler(6), Joshua Sonett(6), Kōichi Goto(6), Joshua C. Curtin(6), Enriqueta Felip(6), Simon K. Cheng(5), Keunchil Park(5), James Chih‐Hsin Yang(5), Amy Roshak(5)